Nutritional cofactor treatment in mitochondrial disorders

Journal of the American Dietetic Association

Volumn 103, Issue 8, 2003, Pages 1029-1038

  Marriage, Barbara ^a   Clandinin, M Thomas ^a   Glerum, D Moira ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIOXIDANT;

COENZYME; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ELECTRON TRANSPORT; HUMAN; METABOLISM; OXIDATIVE PHOSPHORYLATION; REVIEW;

ADENOSINE TRIPHOSPHATE; ANTIOXIDANTS; COENZYMES; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIAL DISEASES; OXIDATIVE PHOSPHORYLATION;

EID: 0042422222     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8223(03)00476-0     Document Type: Article

References (80)

1. Munnich A., and Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 106 (2001) 4-17
2. Applegarth D., Toone J., and Lowry R. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 105 (2000) e10
3. Rauchova H., Drahota Z., and Lenaz G. Function of coenzyme Q in the cell: some biochemical and physiological properties. Physiol Res 44 (1995) 209-216
4. Ernster L., and Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271 (1995) 195-204
5. Fato R., Bertoli E., Parenti Castelli G., and Lenaz G. Fluidizing effect of endogenous ubiquinone in bovine heart mitochondrial membranes. FEBS Lett 172 (1984) 6-10
6. Weber C., Bysted A., and Hllmer G. The coenzyme Q10 content of the average Danish diet. Int J Vitam Nutr Res 67 (1997) 123-129
7. Abe K., Fujimura H., Nishikawa Y., Yorifuji S., Mezaki T., Hirono N., Nishitani N., and Kameyama M. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 83 (1991) 356-359
8. Bresolin N., Bet L., Binda A., Moggio M., Comi G., Nador F., Ferrante C., Carenzi A., and Scarlato G. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 38 (1988) 892-899
9. Nishikawa Y., Takahashi M., Yorifuji S., Nakamura Y., Ueno S., Tarui S., Kozuka T., and Nishimura T. Long-term coenzyme Q10 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 39 (1989) 399-403
10. Goda S., Hamada T., Ishimoto S., Kobayashi T., Goto I., and Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 234 (1987) 62-63
11. Ogasahara S., Yorifuji S., Nishikawa Y., Takahashi M., Wada K., Hazama T., Nakamura Y., Hashimoto S., Kono N., and Tarui S. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 35 (1985) 372-377
12. Yamamoto M., Sato T., Anno M., Ujike H., and Takemoto M. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes with recurrent abdominal symptoms and coenzyme Q10 administration. J Neurol Neurosurg Psychiatry 50 (1987) 1475-1481
13. Ihara Y., Namba R., Kuroda S., Sato T., and Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 90 (1989) 263-271
14. Abe K., Matsuo Y., Kadekawa J., Inoue S., and Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol Sci 162 (1999) 65-68
15. Schneider H., Lemasters J., and Hackenbrock C. Lateral diffusion of ubiquinone during electron transfer in phospholipid- and ubiquinone-enriched mitochondrial membranes. J Biol Chem 257 (1982) 10789-10793
16. Bendahan D., Desnuelle C., Vanuxem D., Confort-Gouny S., Figarella-Branger D., Pellissier J., Kozak-Ribbens G., Pouget J., Serratrice G., and Cozzone P. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 42 (1992) 1203-1208
17. Folkers K., and Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1271 (1995) 281-286
18. Chen R., Huang C., and Chu N. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 37 (1997) 212-218
19. Andersen C., Henriksen J., Hother-Nielsen O., Vaag A., Mortensen S., and Beck-Nielsen H. The effect of coenzyme Q10 on blood glucose and insulin requirement in patients with insulin dependent diabetes mellitus. Mol Aspects Med 18 Suppl (1997) S307-S309
20. Gold R., Seibel P., Reinelt G., Schindler R., Landwehr P., Beck A., and Reichmann H. Phosphorus magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur Neurol 36 (1996) 191-196
21. Barbiroli B., Frassineti C., Martinelli P., Iotti S., Lodi R., Cortelli P., and Montagna P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand) 43 (1997) 741-749
22. Bresolin N., Doriguzzi C., Ponzetto C., Angelini C., Moroni I., Castelli E., Cossutta E., Binda A., Gallanti A., Gabellini S., Piccolo G., Martinuzzzi A., Ciafaloni E., Arnaudo E., Liciardello L., Carenzi A., and Scarlato G. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 100 (1990) 70-78
23. Chan A., Reichmann H., Kogel A., Beck A., and Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 245 (1998) 681-685
24. Suzuki S., Hinokio Y., Ohtomo M., Hirai M., Hirai A., Chiba M., Kasuga S., Satoh Y., Akai H., and Toyota T. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. Diabetologia 41 (1998) 584-588
25. Musumeci O., Naini A., Slonim A., Skavin N., Hadjigeorgiou G., Krawiecki N., Weissman B., Tsao C., Mendell J., Shanske S., De Vivo D., Hirano M., and DiMauro S. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 56 (2001) 849-855
26. Rotig A., Appelkvist E., Geromel V., Chretien D., Kadhom N., Edery P., Lebideau M., Dallner G., Munnich A., Ernster L., and Rustin P. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 356 (2000) 391-395
27. Sobreira C., Hirano M., Shanske S., Keller R., Haller R., Davidson E., Santorelli F., Miranda A., Bonilla E., Mojon D., Barreira A., King M., and DiMauro S. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 48 (1997) 1238-1243
28. Weis M., Mortensen S., Rassing M., Moller-Sonnergaard J., Poulsen G., and Rasmussen S. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol Aspects Med 15 Suppl (1994) S273-S280
29. Wahlqvist M., Wattanapenpaiboon N., Savige G., and Kannar D. Bioavailability of two different formulations of coenzyme Q10 in healthy subjects. Asia Pac J Clin Nutr 7 (1998) 37-40
30. Folkers K., Moesgaard S., and Morita M. A one year bioavailability study of coenzyme Q10 with 3 months withdrawal period. Mol Aspects Med 15 Suppl (1994) S281-S285
31. Weber C. Dietary Intake and Absorption of Coenzyme Q. In: Kagan V., and Quinn P. (Eds). Coenzyme Q: Molecular Mechanisms in Health and Disease (2001), CRC Press, Boca Raton, FL 209-215
32. Zhang Y., Aberg F., Appelkvist E., Dallner G., and Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 125 (1995) 446-453
33. Kaikkonen J., Nyyssonen K., Porkkala-Sarataho E., Poulsen H., Metsa-Ketela T., Hayn M., Salonen R., and Salonen J. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radic Biol Med 22 (1997) 1195-1202
34. Gold D., and Cohen B. Treatment of mitochondrial cytopathies. Semin Neurol 21 (2001) 309-325
35. Przyrembel H. Therapy of mitochondrial disorders. J Inherit Metab Dis 10 Suppl 1 (1987) 129-146
36. Eleff S., Kennaway N., Buist N., Darley-Usmar V., Capaldi R., Bank W., and Chance B. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A 81 (1984) 3529-3533
37. National Academy Press. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids (2000), Institute of Medicine, Washington DC
38. Groff G., Gropper S., and Hunt S. Advanced Nutrition and Human Metabolism (1995), West Publishing Company, St. Paul, MN
39. Klivenyi P., Karg E., Rozsa C., Horvath R., Komoly S., Nemeth I., Turi S., and Vecsei L. alpha-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation. J Neurol Neurosurg Psychiatry 70 (2001) 359-362
40. Kelso G., Porteous C., Hughes G., Ledgerwood E., Gane A., Smith R., and Murphy M. Prevention of mitochondrial oxidative damage using targeted antioxidants. Ann N Y Acad Sci 959 (2002) 263-274
41. Kagan V., Fabrizi G., and Tyurina Y. Independent and Concerted Antioxidant Functions of Coenzyme Q. In: Kagan V., and Quinn P. (Eds). Coenzyme Q: Molecular Mechanisms in Health and Disease (2000), CRC Press, Boca Raton, FL 119-129
42. Tarnopolsky M., and Beal M. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol 49 (2001) 561-574
43. Hagen T., Ingersoll R., Lykkesfeldt J., Liu J., Wehr C., Vinarsky V., Bartholomew J., and Ames A. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. Faseb J 13 (1999) 411-418
44. Marangon K., Devaraj S., Tirosh O., Packer L., and Jialal I. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med 27 (1999) 1114-1121
45. Androne L., Gavan N., Veresiu I., and Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 14 (2000) 327-330
46. Barbiroli B., Medori R., Tritschler H., Klopstock T., Seibel P., Reichmann H., Iotti S., Lodi R., and Zaniol P. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 242 (1995) 472-477
47. Arts W., Scholte H., Bogaard J., Kerrebijn K., and Luyt-Houwen I. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 2 (1983) 581-582
48. Bernsen P., Gabreels F., Ruitenbeek W., and Hamburger H. Treatment of complex I deficiency with riboflavin. J Neurol Sci 118 (1993) 181-187
49. Ogle R., Christodoulou J., Fagan E., Blok R., Kirby D., Seller K., Dahl H., and Thorburn D. Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin. J Pediatr 130 (1997) 138-145
50. Penn A., Lee J., Thuillier P., Wagner M., Maclure K., Menard M., Hall L., and Kennaway N. MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 42 (1992) 2147-2152
51. Scholte H., Busch H., Bakker H., Bogaard J., Luyt-Houwen I., and Kuyt L. Riboflavin-responsive complex I deficiency. Biochim Biophys Acta 1271 (1995) 75-83
52. Bernsen P., Gabreels F., Ruitenbeek W., Sengers R., Stadhouders A., and Renier W. Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Arch Neurol 48 (1991) 334-338
53. Griebel V., Krageloh-Mann I., Ruitenbeek W., Trijbels J., and Paulus W. A mitochondrial myopathy in an infant with lactic acidosis. Dev Med Child Neurol 32 (1990) 528-531
54. Vergani L., Barile M., Angelini C., Burlina A., Nijtmans L., Freda M., Brizio C., Zerbetto E., and Dabbeni-Sala F. Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies. Brain 122 Pt 12 (1999) 2401-2411
55. Addison R., and McCormick D. Biogenesis of flavoprotein and cytochrome components in hepatic mitochondria from riboflavin-deficient rats. Biochem Biophys Res Commun 81 (1978) 133-138
56. Bar-Meir M., Elpeleg O., and Saada A. Effect of various agents on adenosine triphosphate synthesis in mitochondrial complex I deficiency. J Pediatr 139 (2001) 868-870
57. Naito E., Ito M., Takeda E., Yokota I., Yoshijima S., and Kuroda Y. Molecular analysis of abnormal pyruvate dehydrogenase in a patient with thiamine-responsive congenital lactic academia. Pediatr Res 36 (1994) 340-346
58. Lou H. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamin in patients with Kearns-Sayre syndrome. Arch Neurol 38 (1981) 469
59. Sato Y., Nakagawa M., Higuchi I., Osame M., Naito E., and Oizumi K. Mitochondrial myopathy and familial thiamin deficiency. Muscle Nerve 23 (2000) 1069-1075
60. Majamaa K., Rusanen H., Remes A., Pyhtinen J., and Hassinen I. Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci 58 (1996) 691-699
61. Argov Z., Bank W., Maris J., Eleff S., Kennaway N., Olson R., and Chance B. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: A 31P-NMR follow-up study. Ann Neurol 19 (1986) 598-602
62. Toscano A., Fazio M., Vita G., Cannavo S., Bresolin N., Bet L., Prelle A., Barbiroli B., Iotti S., and Zaniol P. Early-onset cerebellar ataxia, myoclonus and hypogonadism in a case of mitochondrial complex III deficiency treated with vitamins K3 and C. J Neurol 242 (1995) 203-209
63. Wijburg F., Barth P., Ruitenbeek W., Wanders R., Vos G., Ploos van Amstel S., and Schutgens R. Familial NADH: Q1 oxidoreductase (complex I) deficiency: variable expression and possible treatment. J Inherit Metab Dis 12 Suppl 2 (1989) 349-351
64. Suttie J. Vitamin K-dependent carboxylase. Annu Rev Biochem 54 (1985) 459-477
65. Shoffner J. Oxidative Phosphorylation Diseases. The metabolic & molecular bases of inherited disease (2001), McGraw-Hill, New York, NY 2367-2423
66. Persky A., and Brazeau G. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 53 (2001) 161-176
67. Montagna P., Martinelli P., Cortelli P., Zaniol P., Lugaresi E., and Barbiroli B. Brain 31P-magnetic resonance spectroscopy in mitochondrial cytopathies. Ann Neurol 31 (1992) 451-452
68. Radda G., Odoom J., Kemp G., Taylor D., Thompson C., and Styles P. Assessment of mitochondrial function and control in normal and diseased states. Biochim Biophys Acta 1271 (1995) 15-19
69. Harris R., Soderlund K., and Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci (Lond) 83 (1992) 367-374 7
70. Tarnopolsky M., Roy B., and MacDonald J. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20 (1997) 1502-1509
71. De Vivo D., and Tein I. Primary and secondary disorders of carnitine metabolism. International Pediatrics 5 (1990) 134-141
72. Carter A., Abney T., and Lapp D. Biosynthesis and metabolism of carnitine. J Child Neurol 10 Suppl 2 (1995) S3-S7
73. Angelini C., Vergani L., and Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. Crit Rev Clin Lab Sci 29 (1992) 217-242
74. Hsu C., Chuang Y., Tsai J., Jong H., Shen Y., Huang H., Chen H., Lee H., Pang C., Wei Y., and Chen S. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 92 (1995) 252-255
75. Tein I., De Vivo D., Ranucci D., and DiMauro S. Skin fibroblast carnitine uptake in secondary carnitine deficiency disorders. J Inherit Metab Dis 16 (1993) 135-146
76. Campos Y., Huertas R., Lorenzo G., Bautista J., Gutierrez E., Aparicio M., Alesso L., and Arenas J. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 16 (1993) 150-153
77. Arenas J., Gonzalez-Crespo M., Campos Y., Martin M., Cabello A., and Gomez-Reino J. Abnormal carnitine distribution in the muscles of patients with idiopathic inflammatory myopathy. Arthritis Rheum 39 (1996) 1869-1874
78. Stanley C. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. Adv Pediatr 34 (1987) 59-88
79. Peterson P. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1271 (1995) 275-280 80
80. Matthews P., Ford B., Dandurand R., Eidelman D., O'Connor D., Sherwin A., Karpati G., Andermann F., and Arnold D. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 43 (1993) 884-890